Concepedia

Author

Nobuyuki Yamamoto

Shizuoka Cancer CenterORCID

Also Known As

Hirofumi Suyama, Kazuhiro Yoshida, Masahiro Endo, Masahiro Fukuoka, Masanori Nakanishi, N Yamamoto, N. YAMAMOTO, N. Yamamoto, NOBUYUKI YAMAMOTO, Natsumi Yamamoto

1K

Publications

28.1K

Citations

73

H-Index

144

Concepts

All Affiliations

Shizuoka Cancer CenterWakayama Medical UniversityKindai UniversityNational Cancer Center Hospital EastNational Hospital Organization Kyushu Cancer Center
NY

About

Nobuyuki Yamamoto is an author at Shizuoka Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

51

161

12.4K

2

Health Sciences

24

46

2.6K

3

Engineering

3

3

120

4

Allergy

3

3

151

5

Public Health

2

2

72

Nobuyuki Yamamoto

×

328

Publications

25.6K

Citations

72

H-Index

YearCitations

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto,

Journal of Clinical Oncology

2013

3.2K

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler,

The Lancet Oncology

2015

1.6K

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater,

The Lancet Oncology

2015

963

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo,

The Lancet

2017

895

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto,

The Lancet Oncology

2019

594

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Takashi Seto, Katsuyuki Kiura, Makoto Nishio,

The Lancet Oncology

2013

576

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Toshiaki Takahashi, Takeharu Yamanaka, Takashi Seto,

The Lancet Oncology

2017

515

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

Koichi Sato, Hiroaki Akamatsu, Eriko Murakami,

Lung Cancer

2017

372

Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

Riichiroh Maruyama, Yutaka Nishiwaki, Tomohide Tamura,

Journal of Clinical Oncology

2008

364

Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Masahiko Ando, Isamu Okamoto, Nobuyuki Yamamoto,

Journal of Clinical Oncology

2006

356

Page 1